Brief: Clovis Oncology Submits Applications For Rubraca Label Expansion In The US And European Union
13/09/2022 13:34
Sept 13 (Reuters) - Clovis Oncology Inc CLVS.O :
* CLOVIS ONCOLOGY SUBMITS APPLICATIONS FOR RUBRACA® LABEL
EXPANSION IN THE US AND EUROPEAN UNION AS FIRST-LINE MAINTENANCE
TREATMENT IN WOMEN WITH ADVANCED OVARIAN CANCER
* CLOVIS ONCOLOGY INC - SAFETY OF RUBRACA OBSERVED IN
ATHENA-MONO
WAS CONSISTENT WITH BOTH CURRENT US AND EUROPEAN LABELS
* CLOVIS ONCOLOGY - SUBMISSIONS BASED ON DATA FROM PHASE 3
ATHENA
TRIAL EVALUATING RUBRACA MONOTHERAPY VERSUS PLACEBO
(ATHENA-MONO) PRESENTED AT ASCO 2022
Source text for Eikon: ID:nBw2Z8hgGa
Further company coverage: CLVS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clovis Oncology
See all newsBrief: Clovis Oncology Inc - On April 5, 2023, Entered Into Asset Purchase Agreement With Pharma& To Sell Product Business For Upfront Payment Of $70 Million
Brief: Clovis Oncology Enters Into Financing Agreement
Brief: Clovis Oncology Inc Received Written Notice From Nasdaq That Company's Common Stock Will Be Delisted From Nasdaq
U.S. STOCKS ON THE MOVE-Nike, Faraday Future, PBF Energy
U.S. STOCKS ON THE MOVE-Natural gas, Box Inc, Weber